Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | ME2 | P23368 | 1/20 | 0.44 |
| ▸ | ME1 | P48163 | 1/20 | 0.44 |
| ▸ | ME3 | Q16798 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22638133 | 0.87 | GPR119 (0.50) | GPR119ME2ME1ME3RET | |
| SCHEMBL22644667 | 0.86 | DRD4 (0.45) | HRH3DRD4 | |
| SCHEMBL22644615 | 0.84 | DRD2 (0.47) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL22644671 | 0.83 | SLC6A2 (0.44) | DRD2DRD4 | |
| SCHEMBL22644660 | 0.82 | HTR1A (0.36) | GPR119RETDRD2DRD4 | |
| SCHEMBL29749666 | 0.82 | HTR1A (0.36) | GPR119RETDRD2DRD4 | |
| SCHEMBL22644616 | 0.82 | CXCR3 (0.43) | DRD2DRD4 | |
| SCHEMBL25272575 | 0.82 | PPARG (0.45) | PPARADRD2DRD3HRH3DRD4 | |
| SCHEMBL31570895 | 0.82 | PPARG (0.45) | PPARADRD2DRD3HRH3DRD4 | |
| SCHEMBL22644650 | 0.81 | PDK2 (0.36) | RETDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325708-B2 | Adenosine 2 receptor antagonists | NEKTAR THERAPEUTICS (US) | 2025-06-10 | — | — | US | disclosed |
| US-20220235056-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS | 2022-07-28 | — | — | US | disclosed |
| WO-2020227156-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235056-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | GPR119 70/4885ME2 1300/4885ME1 4360/4885 |
| US-12325708-B2 | Adenosine 2 receptor antagonists | ADORA2A, ADORA2B, ADORA3 | GPR119 70/4885ME2 1300/4885ME1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.